Literature DB >> 7723794

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

M E Taplin1, G J Bubley, T D Shuster, M E Frantz, A E Spooner, G K Ogata, H N Keer, S P Balk.   

Abstract

BACKGROUND: Metastatic prostate cancer is a leading cause of cancer-related death in men. The rate of response to androgen ablation is high, but most patients relapse as a result of the outgrowth of androgen-independent tumor cells. The androgen receptor, which binds testosterone and stimulates the transcription of androgen-responsive genes, regulates the growth of prostate cells. We analyzed the androgen-receptor genes from samples of metastatic androgen-independent prostate cancers to determine whether mutations in the gene have a role in androgen independence.
METHODS: Complementary DNA was synthesized from metastatic prostate cancers in 10 patients with androgen-independent prostate cancer, and the expression of the androgen-receptor gene was estimated by amplification with the polymerase chain reaction. Exons B through H of the gene were cloned, and mutations were identified by DNA sequencing. The functional effects of the mutations were assessed in cells transfected with mutant genes.
RESULTS: All androgen-independent tumors expressed high levels of androgen-receptor gene transcripts, relative to the levels expressed by an androgen-independent prostate-cancer cell line (LNCaP). Point mutations in the androgen-receptor gene were identified in metastatic cells from 5 of the 10 patients examined. One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line. The mutations were not detected in the primary tumors from of the two patients. Functional studies of two of the mutant androgen receptors demonstrated that they could be activated by progesterone and estrogen.
CONCLUSIONS: Most metastatic androgen-independent prostate cancers express high levels of androgen-receptor gene transcripts. Mutations in androgen-receptor genes are not uncommon and may provide a selective growth advantage after androgen ablation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723794     DOI: 10.1056/NEJM199505253322101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  301 in total

1.  The transmission/disequilibrium test and parental-genotype reconstruction for X-chromosomal markers.

Authors:  S Horvath; N M Laird; M Knapp
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

Review 2.  Prostate cancer: 11. Alternative approaches and the future of treatment.

Authors:  J Trachtenberg; J Crook; I F Tannock
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

3.  Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Authors:  Kush Dalal; Meixia Che; Nanette S Que; Aishwariya Sharma; Rendong Yang; Nada Lallous; Hendrik Borgmann; Deniz Ozistanbullu; Ronnie Tse; Fuqiang Ban; Huifang Li; Kevin J Tam; Mani Roshan-Moniri; Eric LeBlanc; Martin E Gleave; Daniel T Gewirth; Scott M Dehm; Artem Cherkasov; Paul S Rennie
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

Review 4.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 5.  Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Chaitanya Divgi; Steven Larson; Howard I Scher
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

6.  Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.

Authors:  Yaming Qiao; Lu Wang; Li-Qun Cai; Chen Tan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  J Urol       Date:  2011-01       Impact factor: 7.450

Review 7.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 8.  Concept and viability of androgen annihilation for advanced prostate cancer.

Authors:  James L Mohler
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

9.  Implication of androgen receptor in urinary bladder cancer: a critical mini review.

Authors:  Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

10.  Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Authors:  Dennis J van de Wijngaart; Michel Molier; Scott J Lusher; Remko Hersmus; Guido Jenster; Jan Trapman; Hendrikus J Dubbink
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.